Cargando…
Vaccine market and production capabilities in the Americas
In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals’ d...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042620/ https://www.ncbi.nlm.nih.gov/pubmed/33849635 http://dx.doi.org/10.1186/s40794-021-00135-5 |
_version_ | 1783678156228526080 |
---|---|
author | Ortiz-Prado, Esteban Espín, Estefanía Vásconez, Jorge Rodríguez-Burneo, Nathalia Kyriakidis, Nikolaos C. López-Cortés, Andrés |
author_facet | Ortiz-Prado, Esteban Espín, Estefanía Vásconez, Jorge Rodríguez-Burneo, Nathalia Kyriakidis, Nikolaos C. López-Cortés, Andrés |
author_sort | Ortiz-Prado, Esteban |
collection | PubMed |
description | In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals’ distribution and production. Some Latin American countries rank in the top 20 of worldwide vaccine manufacturers, with Cuba, Brazil, México and Colombia have a self-sufficient vaccine production of 72.7%, 54,2%; 25%; and 7.7%, respectively, of the national vaccine demand. On the other hand, the rest of Latin American countries cannot satisfy their demand for vaccines, and most of their efforts are associated with the distribution within their health systems rather than in transferring technology. Based on this literature review, the results suggest an increasing growth vaccine demand, not only for their growing populations and previously established demand but also for the recently exerted pressure due to the COVID-19 pandemic. Because the American continent has a marked inequality between the hegemonic producers of vaccines, the exporters, and those that depend heavily on importing these products, this could assert technological dependence in countries with rapid population growth and jeopardize the effectiveness of the two vaccination plans. |
format | Online Article Text |
id | pubmed-8042620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80426202021-04-13 Vaccine market and production capabilities in the Americas Ortiz-Prado, Esteban Espín, Estefanía Vásconez, Jorge Rodríguez-Burneo, Nathalia Kyriakidis, Nikolaos C. López-Cortés, Andrés Trop Dis Travel Med Vaccines Review In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals’ distribution and production. Some Latin American countries rank in the top 20 of worldwide vaccine manufacturers, with Cuba, Brazil, México and Colombia have a self-sufficient vaccine production of 72.7%, 54,2%; 25%; and 7.7%, respectively, of the national vaccine demand. On the other hand, the rest of Latin American countries cannot satisfy their demand for vaccines, and most of their efforts are associated with the distribution within their health systems rather than in transferring technology. Based on this literature review, the results suggest an increasing growth vaccine demand, not only for their growing populations and previously established demand but also for the recently exerted pressure due to the COVID-19 pandemic. Because the American continent has a marked inequality between the hegemonic producers of vaccines, the exporters, and those that depend heavily on importing these products, this could assert technological dependence in countries with rapid population growth and jeopardize the effectiveness of the two vaccination plans. BioMed Central 2021-04-13 /pmc/articles/PMC8042620/ /pubmed/33849635 http://dx.doi.org/10.1186/s40794-021-00135-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Ortiz-Prado, Esteban Espín, Estefanía Vásconez, Jorge Rodríguez-Burneo, Nathalia Kyriakidis, Nikolaos C. López-Cortés, Andrés Vaccine market and production capabilities in the Americas |
title | Vaccine market and production capabilities in the Americas |
title_full | Vaccine market and production capabilities in the Americas |
title_fullStr | Vaccine market and production capabilities in the Americas |
title_full_unstemmed | Vaccine market and production capabilities in the Americas |
title_short | Vaccine market and production capabilities in the Americas |
title_sort | vaccine market and production capabilities in the americas |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042620/ https://www.ncbi.nlm.nih.gov/pubmed/33849635 http://dx.doi.org/10.1186/s40794-021-00135-5 |
work_keys_str_mv | AT ortizpradoesteban vaccinemarketandproductioncapabilitiesintheamericas AT espinestefania vaccinemarketandproductioncapabilitiesintheamericas AT vasconezjorge vaccinemarketandproductioncapabilitiesintheamericas AT rodriguezburneonathalia vaccinemarketandproductioncapabilitiesintheamericas AT kyriakidisnikolaosc vaccinemarketandproductioncapabilitiesintheamericas AT lopezcortesandres vaccinemarketandproductioncapabilitiesintheamericas |